Tepezza Hearing Loss Lawsuit 2026 | Claims, Compensation & Legal Updates

The Tepezza hearing loss lawsuit has become a major legal battle as more patients report serious ear and hearing problems after receiving Tepezza infusions for Thyroid Eye Disease. Many people say they were not properly warned about the risk of lasting hearing damage and are now taking legal action seeking compensation for medical costs and the long-term impact on their quality of life. As the litigation grows, new updates continue to shape what claimants can expect in 2026. This page will cover who qualifies to file a claim, expected settlement and compensation outlook, and the latest legal updates in the Tepezza lawsuit.

What the Tepezza Hearing Loss Lawsuit Is About?

The Tepezza hearing loss lawsuit is about patients claiming that the drug Tepezza caused hearing problems after treatment. Tepezza is used for Thyroid Eye Disease and is given as a series of infusions. Many people who took it later reported issues like hearing loss, ringing in the ears, muffled hearing, and other long-term ear problems. The lawsuit says the drug manufacturer failed to properly warn doctors and patients that Tepezza could seriously affect hearing. It also argues that the risk was higher than what the company showed in the original studies and that better warnings or updated safety information should have been provided sooner.

People filing these lawsuits say they would not have taken Tepezza or would have chosen a different treatment if they had known the real risk. They want compensation for medical costs, long-term disabilities, pain and suffering, and the impact that permanent or ongoing hearing damage has on daily life. The lawsuits are grouped together in a large litigation so that the cases can move forward more efficiently, but each patient’s injuries are still considered individually.

Timeline of the Tepezza Hearing Loss Litigation

Here is the complete timeline that tracks every major update in the Tepezza hearing loss litigation, from the earliest lawsuits to the most recent developments in the MDL.

August 22, 2025 – Updated Bellwether Timeline Sets Four Trial Dates Into 2027

The schedule for the first Tepezza hearing loss bellwether trial has been pushed back, with jury selection now planned for August 3, 2026. Three more trials are slated to follow on September 28, 2026, November 30, 202,6, and February 1, 2027. Each proceeding is expected to run three to four weeks, making this trial phase a major driver of the litigation’s future direction.

August 17, 2025 – MDL Continues Expansion as Filing Count Reaches 260

The Tepezza multidistrict litigation has grown once again, now totaling 260 active lawsuits. Each new case reflects a rising number of patients claiming hearing injuries linked to Tepezza infusions and adds pressure to move the litigation forward toward settlement or trial.

August 2, 2025 – New Filing Highlights Alleged Failure to Warn on Hearing Damage Risks

A recently added MDL complaint from an Indiana woman states she developed permanent hearing damage and ongoing tinnitus after completing Tepezza infusions for thyroid eye disease between July 2021 and January 2022. According to the filing, she agreed to treatment, believing the drug was a promising breakthrough, yet she was never told about the potential for lasting ear and hearing problems.

The lawsuit points out that Tepezza’s label at the time did not include any statements about permanent hearing loss or tinnitus and did not encourage hearing evaluations during treatment. A warning was not added to the label until July 2023, long after her infusions ended. The complaint argues that Horizon Therapeutics had early information suggesting a high rate of hearing complications from internal research, including Study 401, which reportedly showed hearing-related side effects in a significant portion of users by March 2020. The lawsuit also states that internal concerns were ignored and that a whistleblower who tried to raise the issue was removed from the company.

July 21, 2025 – Updated MDL Schedule Pushes First Tepezza Trial to Mid-2026

The court overseeing the Tepezza multidistrict litigation has approved a revised timetable that extends expert discovery and postpones the opening bellwether trial until June 2026. Plaintiffs’ experts will now be deposed between August 25 and September 19, 2025, followed by defense expert disclosures and depositions through October 17, 2025.

Briefing on Rule 702 / Daubert challenges is due January 9, 2026, with oral argument planned for January 19–23. The court intends to issue rulings by February 9, 2026, paving the way for summary judgment motions, which will be filed between February 6 and March 20, 2026.

The first hearing-loss bellwether trial is now scheduled to kick off on June 8, 2026, with three additional trials set for August 3, September 28, and November 30, 2026. As a result, a broad Tepezza settlement is unlikely before late 2026.

July 7, 2025 – Nevada Woman Files New Suit After Developing Severe Hearing Problems Post-Tepezza

A new complaint filed just before the holiday moves another plaintiff into the MDL against Horizon Therapeutics and its successor entities. The Nevada resident says she developed permanent hearing damage and tinnitus after undergoing Tepezza infusions to treat thyroid eye disease or Graves’ disease.
Her treatment began in July 2023, shortly before Horizon revised the drug’s label to warn about the risk of long-term auditory impairment and recommend hearing monitoring during therapy.

July 2, 2025 – MDL Sees Noticeable Growth as Filing Activity Picks Up

The Tepezza multidistrict litigation continues to expand, with the number of pending lawsuits rising to 236. This increase marks one of the more significant monthly jumps so far and reflects ongoing momentum among individuals claiming permanent hearing loss and tinnitus after Tepezza treatments.

June 27, 2025 – Early 2026 Settlement Forecast Gains Traction Among Observers

Some legal analysts believe the Tepezza litigation may resolve before the first bellwether trial even begins. While nothing is guaranteed, many expect settlement talks to intensify and potentially conclude in the early part of next year, creating the possibility of payouts ahead of trial.

May 1, 2025 – Case Count Climbs to 217 as Judge Blocks Horizon’s Bid to End MDL

There are now 217 active Tepezza hearing loss lawsuits, a small increase from last month. Although Horizon recently failed in its attempt to get the entire MDL dismissed, this ruling is unlikely to trigger a surge in new filings, as few observers expected the motion to succeed.

April 9, 2025 – Court Rejects Request for Additional Depositions of Tepezza Patient Access Liaisons

The MDL judge denied the plaintiffs’ effort to compel depositions of six Patient Access Liaisons and one Horizon sales representative. Plaintiffs argued these individuals communicated directly with patients and possessed vital case knowledge, but the court ruled the request exceeded the allowed 30-deposition cap without showing good cause.

The judge noted that PALs had been identified as custodians long before the request and that adding seven more depositions so late in discovery would place a significant burden on the defense. As a result, the motion was rejected, and the current discovery limits remain unchanged.

April 1, 2025 – Case Count Reaches 207 as Attention Turns to 2026 Trial Schedule

The Tepezza MDL has grown to 207 lawsuits, rising slightly from 203 earlier in March. The pace remains gradual, but the upcoming bellwether trial calendar is now the central focus. The first of four trials is expected to start in March 2026, and both sides are currently narrowing down their trial selections from the pool of eligible cases.

March 25, 2025 – Bellwether Trials Set to Influence Litigation Path and Settlement Pressure

Plans for the first bellwether trials have been finalized, with proceedings scheduled from April through September 2026. These early trials are intended to serve as test cases that help determine the strengths and weaknesses of each side’s arguments. While the outcomes will not automatically apply to every lawsuit, they are likely to be a major driver of settlement negotiations across the litigation.

Legal observers are watching closely to see whether trial results will push Horizon toward meaningful settlement offers or whether the company will continue defending the claims aggressively.

March 4, 2025 – MDL Adds Four New Cases as Filing Trend Remains Steady

The Tepezza hearing loss litigation entered February with 203 pending lawsuits and has increased to 207. This month’s case growth is nearly identical to the filing pattern seen in the previous cycle, signaling consistent but modest expansion of the MDL.

January 11, 2025 – Slow Filing Activity Continues With MDL Reaching 200 Cases

The Tepezza MDL showed only slight momentum over the last two months. After adding 11 new lawsuits in November, the court received just 9 more filings in December, bringing the total number of active cases to 200. This underlines ongoing slow growth in the litigation.

December 30, 2024 – Bellwether Candidate Hearing Scheduled to Narrow First Trial Picks

The court has set January 28, 2025, for a hearing to finalize which lawsuits will become the first Tepezza bellwether trials. Twelve discovery cases were previously chosen in June, with four selected by plaintiffs, four by defendants, and four randomly chosen by the judge. From this group, three lawsuits will be picked for the opening trial sequence and will then undergo detailed case-specific discovery to prepare them for presentation to a jury.

December 2, 2024 – Filing Spike in November Strengthens Expectations of Faster Settlement Talks

The Tepezza MDL experienced a sharp rise in activity during November as 11 new lawsuits were added, compared to only two filed the month before. Despite the modest overall size of the litigation, many believe this case count is manageable enough for Horizon to eventually settle without major financial disruption. Combined with the strength of the plaintiffs’ allegations, this surge reinforces the view that a long, drawn-out MDL is unlikely.

November 13, 2024 – Judge Criticizes Defense Obstruction in Discovery Ruling

The court issued a ruling in response to a previously reported discovery motion, siding heavily with the plaintiffs. The judge found that defense objections during depositions were unnecessarily disruptive and not supported by the rules of procedure. The court also stated that objections over authentication were misplaced because documents produced in discovery are presumed authenticated. Although this ruling does not directly shift the pace of the case, it signals that the judge is taking note of obstructive tactics.

November 4, 2024 – Plaintiffs Challenge Speaking Objections and Coaching During Depositions

Plaintiffs have filed a motion accusing Horizon’s legal team of repeatedly interfering with testimony during a deposition of their Director of Regulatory Affairs. According to the motion, defense attorneys issued lengthy objections that appeared aimed at influencing answers rather than addressing form or procedure. Plaintiffs say these objections increased when questioning involved important regulatory documents tied to Tepezza’s approval. They argue that framing the documents as irrelevant or unfamiliar to the witness was a deliberate attempt to steer testimony. The motion seeks to prevent further interruptions of this kind in upcoming depositions.

November 1, 2024 – MDL Grows to 180 Cases but Continues to Expand Slowly

The Tepezza multidistrict litigation added two new lawsuits in October, bringing the total to 180 active cases. The pace of filings remains slow, suggesting that many affected patients have not yet come forward. Although the MDL is still relatively small, this may benefit those already involved by supporting quicker litigation and potentially higher settlement values.

Also Read: Average Payout for Ankle Injury With Surgery

October 29, 2024 – One Bellwether Case Removed After Judge Applies Michigan Immunity Law

Horizon successfully dismissed one of the twelve bellwether candidates after Judge Durkin determined that Michigan law governed the claim, since the plaintiff used Tepezza and experienced injuries in Michigan. Horizon relied on an older Michigan statute that shielded FDA-approved drugs from product liability suits. While the law has since been amended, it cannot be applied retroactively, allowing Horizon to eliminate the case.

October 18, 2024 – Oklahoma Plaintiff Alleges Permanent Hearing Damage From Tepezza Infusions

A newly filed lawsuit accuses Horizon Therapeutics of causing permanent hearing loss in a patient who received Tepezza infusions for thyroid eye disease between November 2022 and February 2023. The complaint states that Horizon failed to give adequate warnings about serious auditory risks, even though internal reports and clinical data allegedly showed danger long before the company updated the label in July 2023. The plaintiff is seeking compensation and punitive damages, arguing that earlier disclosure of known risks could have prevented lasting harm.

October 1, 2024 – MDL Inches Up to 178 Cases as Filing Trend Remains Modest

The Tepezza hearing loss litigation added five new lawsuits in September, increasing the total to 178 pending cases. Growth is slow and steady, and the MDL is not expected to become very large. However, attorneys involved in the litigation still believe the claims carry strong settlement potential for current plaintiffs.

September 17, 2024 – New Lawsuit Filed by Florida Patient Alleging Irreversible Hearing Injuries

A woman from Florida filed a new claim against Horizon Therapeutics USA after receiving Tepezza treatments from October 2020 through June 2021. She alleges the drug caused permanent hearing loss and that Horizon did not warn patients or doctors about auditory risks, despite studies suggesting a link.

According to the complaint, the warning label did not mention permanent hearing impairment or tinnitus until July 2023, long after her infusions. The lawsuit accuses Horizon of postponing critical safety updates and failing to conduct adequate research and asks the court for both compensatory and punitive damages.

September 3, 2024 – MDL Sees Largest Monthly Increase So Far With 33 New Claims

The month of August brought 33 additional filings to the Tepezza hearing loss MDL, marking the largest monthly rise to date. The total number of lawsuits now stands at 173, showing significantly higher activity than usual for this litigation.

August 18, 2024 – Parties Reach Deal on Deposition Limits and Scheduling

According to a new Joint Status Report, the involved parties have reached an agreement on how many depositions will take place and when they will occur. Depositions will be divided into two waves, with one group completed by February 14, 2025, and the remainder finished by April 10, 2025. With deposition logistics settled, many observers continue to believe that settlements may occur before the first trial scheduled for 2026.

August 1, 2024 – Case Count Reaches 148 as MDL Continues Slow Expansion

The Tepezza MDL added 10 new lawsuits in July, raising the total to 148 cases. Despite steady litigation growth, the number of potential claimants appears far higher than the number of people filing lawsuits so far. Individuals who suspect their hearing loss may be linked to Tepezza are encouraged to consult an attorney promptly to protect their rights.

July 30, 2024 – Defense Seeks to Trim Discovery, But Push Likely to Fail

Horizon has requested that the court throw out the claims, a move widely expected to be denied. At the same time, attorneys on both sides met to negotiate how many corporate and expert witness depositions would be allowed. The defense is pushing to drastically reduce corporate depositions, while plaintiffs insist on broad access. The MDL judge is expected to receive a joint report later this week.

July 18, 2024 – Settlement Talks Scheduled, Expectations Remain Cautious

A mediation session aimed at reaching a Tepezza settlement is set for this month. While many hope the discussion leads to progress, attorneys acknowledge that a full resolution remains uncertain at this stage.

July 14, 2024 – Trial Calendar Announced: Bellwethers Locked In Through 2026

The court released the timeline for four bellwether trials, providing structure to the MDL:

Bellwether	Date
First Trial	March 9, 2026
Second Trial	May 4, 2026
Third Trial	June 29, 2026
Fourth Trial	August 24, 2026

Although this is welcome progress, the downside is that the first trial is still nearly two years away. Settlement before trial remains a possibility due to the relatively modest size of the litigation.

July 1, 2024 – New Plaintiff Alleges Permanent Damage After Three Infusions

The MDL continues to expand, adding 19 new filings last month. One recently filed case involves a Colorado plaintiff who received three Tepezza infusions between May and June 2022 and now reports severe and lasting auditory damage. The lawsuit claims the manufacturer knew—or should have known—from scientific data, post-market surveillance, and patient experience that the drug could cause major hearing impairment. Despite this, the company allegedly failed to warn patients until the July 17, 2023, label update, which finally advised that hearing testing should occur throughout treatment.

June 5, 2024 – First Trial Set for 2026, With Three More to Follow

The inaugural bellwether trial is scheduled for March 9, 2026, followed by additional trials on May 4, June 29, and August 24 of the same year. Although these dates are not imminent, many legal experts anticipate that a global settlement could eventually emerge before the first jury is seated, partly because the total number of pending cases is far smaller than originally predicted.

June 2, 2024 – Horizon Identifies Four Plaintiffs for Bellwether Group

Horizon has submitted its picks for the bellwether pool, selecting four women whose cases will be used in the initial round of early test trials.

May 20, 2024 – First Tepezza Trial Scheduled; Parties Ordered to Map Out Discovery Plan

The court has officially placed the first bellwether trial on the calendar for March 9, 2026. Judge Durkin has directed both sides to work together and present a joint proposal outlining deadlines for discovery and the bellwether case selection process leading up to trial.

April 13, 2024 – Status Conference Adjusted, New Court Dates Confirmed

The status hearing that was supposed to take place on April 22, 2024, before the magistrate judge has been removed from the schedule. The joint status report deadline has been moved from April 18 to April 24, 2024. Separately, an in-person status conference with Judge Durkin is set for May 1, 2024, at 1:30 p.m.

April 9, 2024 – Florida Plaintiff Claims Severe Permanent Hearing Damage

A newly filed lawsuit alleges that a Florida man suffered profound and lasting auditory injuries after Tepezza infusions administered between February and July 2022 in Ohio. According to the complaint, neither the patient nor his doctors were informed of the risk of permanent hearing loss or tinnitus, and no guidance was provided about pre-treatment or ongoing audiology monitoring. The label change warning about serious hearing impairment did not appear until July 2023. The plaintiff is seeking compensation for irreversible injuries attributed to the drug.

April 1, 2024 – MDL Growth Continues, But at a Very Modest Pace

The Tepezza hearing loss MDL expanded by only eight new filings over the last month, raising the total number of active cases to 101. When the multidistrict litigation launched in August 2023, the docket contained 54 lawsuits — showing steady but slow expansion.

March 19, 2024 – Court to Hear Arguments on Attempt to Delay Progress

Oral arguments are scheduled for tomorrow regarding the defense’s attempt to slow the movement toward the first bellwether trials. It remains to be seen whether the judge will tolerate efforts to stretch the timeline.

March 13, 2024 – Defense Requests Two-Month Extension for Bellwether Selections

Horizon’s legal team is pushing for a 60-day delay in selecting the four bellwether hearing-loss cases, citing the need for more time to review medical records and evaluate potential candidates. The strategy mirrors a familiar playbook — defendants frequently attempt to extend deadlines to delay trial pressure. The plaintiffs argue that momentum toward trial is key to moving negotiations and potential settlement forward.

March 1, 2024 – New TED Medication Showing Strong Results May Challenge Tepezza

Encouraging developments are emerging for thyroid eye disease patients. Innovent Biologics completed a successful Phase 3 clinical trial for its Tepezza competitor, IBI311, in China. The study showed 85.8% of participants experienced notable reductions in eye bulging, and no serious adverse events were reported. Innovent is preparing to file for market approval in China, with global expansion anticipated if approvals progress smoothly.

February 15, 2024 – Ongoing Dispute Over Data Protocol May Require Court Resolution

Plaintiffs and defendants remain divided on the plan for handling data from non-custodial sources. If they cannot finalize the protocol, both sides must file simultaneous submissions to the court by February 28, 2024, at 5:00 p.m. CST. The matter is expected to be addressed during the March 6 status conference.

February 8, 2024 – Agreement on Document Production Signals Very Long Discovery Phase

The parties have reached an agreement on how Horizon will turn over internal documents in the Tepezza hearing loss lawsuits. However, the production will not be completed until the end of 2024, signaling a lengthy discovery process. Plaintiffs believe emails, meeting notes, and internal research may reveal what Horizon knew about hearing-related risks and when. While some anticipate a settlement before trial, sustained pressure on the defense remains essential.

January 15, 2024 – Three Additional Claims Filed, Tepezza MDL Now at 74 Cases

Between mid-December and mid-January, three new hearing loss lawsuits were transferred to the MDL, bringing the total to 74 (75 when including a separate 2024 filing that has not yet been docketed). Although this litigation is not projected to become massive, the smaller number of claimants may ultimately translate to faster settlements and potentially higher compensation values per case.

January 9, 2024 – Parties Request 60-Day Extension to Finalize Bellwether Trial Candidates

Attorneys on both sides have asked Judge Durkin for an additional 60 days to evaluate medical records and determine which cases should be included in the Initial Bellwether Discovery Pool. These early test trials are expected to play a major role in establishing settlement benchmarks. The request modifies the original November order, which gave plaintiffs 60 days and defendants 90 days to make their selections before the court randomly added four more cases to bring the pool to 12.

January 8, 2024 – Plaintiffs Push Back Against Efforts to Delay Case Management Conference

Six months after the JPML centralized Tepezza hearing-loss claims before Judge Durkin, plaintiffs argue that the litigation is progressing far too slowly. They filed an opposition after Horizon sought to postpone the upcoming case management conference, asserting that defendants are using delay tactics and that unresolved issues — such as the production protocol — require judicial intervention. Plaintiffs stress that keeping regular conferences on the calendar is critical to moving the MDL forward.

December 18, 2023 – Case Count Rises to 71 as MDL Sees Its First Noticeable Uptick

Over the past month, 12 additional Tepezza hearing-loss lawsuits were added to the MDL, doubling the pace of filings from the prior reporting period. While the overall MDL volume remains modest, the increase could signal an upward trend heading into 2024.

December 1, 2023 – Discovery Friction Begins Early in the MDL

Plaintiffs filed a detailed “Narrative Submission” ahead of the next case management conference, outlining multiple concerns regarding Horizon’s cooperation in early discovery. The filing accuses the defense of dragging its feet in responding to foundational document requests.

November 20, 2023 – Florida Patient Claims Tepezza Left Her With Permanent Hearing Damage

A Florida woman has joined the MDL after receiving Tepezza infusions between August 2022 and April 2023 for thyroid eye disease. Her lawsuit alleges that she developed irreversible hearing loss and persistent tinnitus after treatment, and asserts that Horizon failed to warn physicians and patients about the risk of auditory injury.

November 19, 2023 – Only Five New Transfers, but Small MDL Size May Benefit Claimants

Just five additional cases entered the MDL in the last month, bringing the total to 59. Despite slow growth, the low number of plaintiffs may ultimately favor those already in litigation by making global settlement negotiations more streamlined and time-efficient.

November 6, 2023 – Court Rejects Motion to Dismiss Design-Defect Claims

Horizon was unsuccessful in its attempt to dismiss claims that it should have developed a safer formulation of Tepezza before seeking FDA approval. The court held that federal law does not preempt these “pre-approval design defect” allegations, allowing them to proceed.

November 3, 2023 – Judge Issues Order Establishing Bellwether Case Selection Rules

A new Case Management Order outlines the framework for bellwether selection. Within 60 days, 12 candidate lawsuits will be identified: four selected by plaintiffs, four chosen by defendants, and four randomly selected by the court. These cases will then proceed through fact discovery to prepare for test trials.

September 18, 2023 – MDL Case Total Grows to 54, Still Small but Steadily Increasing

The number of lawsuits has risen from 41 to 54 since June. Although the growth has been gradual, filings are expected to accelerate as more Tepezza users become aware of the litigation.

September 14, 2023 – Magistrate Judge Weisman Assigned to Manage Discovery and Settlement Talks

Magistrate Judge M. David Weisman has been appointed to supervise discovery and settlement procedures in the Tepezza MDL. The initial status conference is scheduled for September 19, 2023, at 9:15 a.m., with dial-in access provided for plaintiffs. Recording the hearing is strictly prohibited under court rules.

September 11, 2023 – Amgen Cleared to Complete $27B Acquisition of Horizon, Taking On Tepezza Liability

Amgen has resolved its antitrust dispute with the FTC, allowing the $27 billion buyout of Horizon Therapeutics to move forward. With the acquisition finalized, Amgen inherits responsibility for the pending Tepezza hearing-loss claims — a meaningful win for plaintiffs given Amgen’s substantial financial resources.

September 10, 2023 — Court Addresses Privilege & Discovery Protections

A status conference was held on September 8, 2023, in the Tepezza multidistrict litigation. During the session, counsel were instructed to submit a jointly drafted order outlining procedures related to Federal Rule of Evidence 502(d), the handling of privileged documents, and a protective order. These measures would allow Horizon’s legal team to share materials during discovery without forfeiting privilege protections.

Magistrate Judge M. David Weisman will be playing a key role in the MDL moving forward, overseeing discovery issues and helping steer the parties toward potential settlement discussions.

September 1, 2023 — Plaintiffs Push for Accelerated Bellwether Trial Track

Attorneys representing Tepezza plaintiffs are advocating for an aggressive timeline to bring the first test trials to the courtroom quickly. Their proposal — discussed at the latest status conference — calls for each side to choose three bellwether candidates, with a condensed fact-discovery window of 150 days.

Once discovery is completed, three of the six lawsuits will be selected for the initial bellwether trials. Horizon’s defense team has offered an alternative plan with a slightly larger pool of 10 bellwether candidates.

August 18, 2023 — New Complaint Filed by Florida Patient Alleging Severe Hearing Damage

A recent filing in MDL 3568 — Mhamdi v. Horizon Therapeutics USA, Inc. — involves a Florida woman who underwent Tepezza infusions for thyroid eye disease from August 2020 through February 2023. She now reports permanent hearing impairment and/or persistent tinnitus.

The lawsuit claims she and her doctors were never warned that Tepezza carries a substantial risk of permanent auditory damage. She contends Horizon failed to disclose these dangers to both patients and the medical community.

August 15, 2023 — MDL Case Count Climbs as Steady Growth Continues

Five additional Tepezza hearing-loss lawsuits were transferred into the MDL over the last month, bringing the total to 46 cases, only three months after the litigation began. While the MDL is not expected to reach the size of some other major pharmaceutical mass torts, attorneys anticipate it will reach 100 filings by year’s end — a prediction that, in hindsight, proved accurate (with 73 cases filed in 2023).

August 2, 2023 — Scheduling Order Still Pending; Filing Pace Fluctuates

The MDL is still awaiting its first major scheduling order establishing key deadlines. Meanwhile, new filings continue to arrive sporadically: only three lawsuits were filed in July, while June produced 16 new filings — the highest monthly total to date.

July 25, 2023 — FDA Tightens Tepezza Safety Warnings Amid Rising Litigation

Horizon Pharmaceuticals faces increasing lawsuits accusing the company of withholding information about the risk of Tepezza-related hearing damage. Adding pressure, the FDA has revised Tepezza’s safety label to feature strong warnings stating that the medication may cause serious and potentially irreversible harm to hearing.
Patients are reminded that medical decisions should never be based on litigation strategy. If symptoms appear, it’s essential to speak with a physician about treatment options.

June 19, 2023 — First MDL Status Conference Scheduled

The federal judge presiding over the newly formed Tepezza MDL will hold the initial status hearing on June 28, 2023, bringing together attorneys from all sides. This first conference will allow Judge Durkin to begin shaping the structure of the litigation and decide who will serve on the plaintiffs’ leadership committee.

June 5, 2023 – Consolidated Tepezza Litigation Officially Begins

The Tepezza hearing loss claims have now been formally grouped into a single multidistrict litigation (MDL) against Horizon Therapeutics USA Inc., marking the official start of coordinated proceedings. The lawsuits accuse the company of failing to alert patients and healthcare providers to the drug’s risk of permanent tinnitus and hearing impairment. Judge Thomas M. Durkin in Chicago has been appointed to manage the MDL. With plaintiffs now working together under a streamlined discovery structure, legal teams believe the strength of the evidence and unified approach will help drive meaningful settlement outcomes for affected individuals.

May 31, 2023 – Ohio Plaintiff Files New Suit Over Post-Infusion Hearing Damage

A recently filed case out of Ohio adds another plaintiff to the growing pool of Tepezza hearing loss litigation. The woman—treated for thyroid eye disease / Graves’ disease—received infusions from April 2021 to October 2021. Her complaint says she was never cautioned that Tepezza could permanently damage her hearing, nor were her doctors informed of the danger. She now reports lasting tinnitus and hearing decline and is seeking compensation for those injuries.

May 22, 2023 – Surge in New Claims Ahead of MDL Decision

As the Judicial Panel on Multidistrict Litigation (JPML) prepares to decide whether to centralize Tepezza lawsuits, filings across the country have accelerated. Ten additional lawsuits were submitted in federal courts within the last week alone. At the same time, Amgen’s planned $27 billion acquisition of Horizon Therapeutics faces uncertainty after the Federal Trade Commission moved to halt the deal.

May 11, 2023 – Horizon Opposes Consolidation of Federal Tepezza Cases

Ahead of the JPML hearing scheduled for May 25, 2023, Horizon Therapeutics has filed a motion opposing MDL formation. The company argues that the number of existing lawsuits is too small to justify consolidation and contends that the total volume of future filings will not be significant. Plaintiffs’ attorneys strongly disagree, pointing to a steady rise in new claims as more patients learn that the drug may cause irreversible auditory damage.

May 8, 2023 – Nationwide Filing Activity Intensifies

Federal courts have seen a sharp uptick in Tepezza-related lawsuits over the past several weeks. When the motion to form an MDL was submitted in March, only 18 federal cases were on record across five districts; since then, seven additional lawsuits have been filed. The Judicial Panel on Multidistrict Litigation is set to evaluate consolidation at the end of the month, meaning the landscape of these lawsuits may soon shift dramatically.

April 26, 2023 – Federal Judges to Decide on Centralized Tepezza Proceedings

The U.S. Judicial Panel on Multidistrict Litigation—tasked with determining whether federal civil actions involving similar issues should be centralized—will evaluate the Tepezza cases on May 25, 2023. If approved, the panel will assign the lawsuits to one federal judge who will oversee coordinated pretrial matters, eliminating repetitive discovery and ensuring consistent rulings. This decision will determine whether the litigation moves forward as a single nationwide proceeding.

April 14, 2023 – Expanded Tepezza Use Approved While Litigation Builds

Even as lawsuits continue stacking up and the court weighs whether to centralize the claims, Horizon is pressing forward with Tepezza’s commercial success. The company announced today that the FDA has approved updated indication language that broadens eligibility for Thyroid Eye Disease (TED) treatment. The shift follows a Phase 4 study showing notably greater reduction in proptosis at week 24 among patients who received Tepezza versus those on placebo. The revised labeling is expected to streamline access and reduce delays for TED patients and providers. Horizon plans to showcase these trial results at an upcoming medical conference and later in a peer-reviewed journal. Realistically, even if the litigation results in major settlements or trial verdicts, the financial upside from Tepezza sales may continue to overshadow liability costs for the company.

April 13, 2023 – Move Filed to Centralize Federal Hearing Loss Claims

A formal request has been submitted to the Judicial Panel on Multidistrict Litigation (JPML) seeking consolidation of the Tepezza hearing loss lawsuits into one coordinated proceeding. The motion identifies 18 product liability actions pending across five federal districts and asks that the potential MDL be assigned to the Northern District of California if approved.

April 4, 2023 – Case Study Strengthens Dose-Response Connection to Hearing Loss

Newly published research from Stanford University supports the concern that Tepezza dosage impacts the likelihood of hearing damage. The report follows a 64-year-old woman who developed substantial bilateral hearing loss after completing a full treatment course in 2021. When therapy was discontinued, her auditory issues resolved. A year later, she resumed Tepezza at a much lower dose and did not experience the same side effects. This documented pattern adds to mounting clinical evidence that Tepezza can trigger hearing impairment.

March 24, 2023 – More Lawsuits Filed; Some Cases Quietly Resolve

Four additional federal lawsuits alleging that Tepezza caused irreversible hearing loss have been filed since the beginning of March. There are now 34 federal actions tied to hearing damage. Thirteen of those cases have been voluntarily dismissed, suggesting they may have reached confidential settlements.

February 28, 2023 – What a Typical Tepezza Lawsuit Alleges

A Tepezza injury complaint generally asserts that the drug caused long-term or permanent auditory damage and that Horizon failed to properly warn patients and physicians about these risks before or during infusion therapy.

February 14, 2023 – Horizon Attempts to Shut Down Claims Through Federal Preemption

Horizon has moved to dismiss the Tepezza hearing loss lawsuits by arguing that federal law blocks—or “preempts”—the plaintiffs’ claims. The dispute centers on the company’s position that the FDA controlled whether and how Tepezza’s warning label could be modified, meaning Horizon should not be held liable for failing to add stronger warnings on its own. Preemption arguments are a familiar defense tactic in drug-related product liability litigation.

January 20, 2023 – Plaintiffs Seek Consolidation of Illinois Tepezza Cases

Attorneys representing individuals injured by Tepezza are pushing to merge ten hearing loss lawsuits currently pending in the Northern District of Illinois. They argue that grouping the cases before a single judge would speed up pretrial progress and avoid repetitive discovery. Horizon opposes the consolidation motion, claiming that the lawsuits involve distinct factual circumstances and therefore should not be handled together. Fewer than 20 federal Tepezza cases were pending nationwide at the time of the filing.

January 18, 2023 – Amgen–Horizon Acquisition Threatened by Shareholder Challenge

Amgen’s plan to purchase Horizon Therapeutics for $116.50 per share has encountered resistance. A group of Amgen investors has filed a lawsuit seeking to block the transaction, alleging concerns that Horizon failed to disclose the full scope of hearing-loss risks tied to Tepezza. The investor challenge adds another layer of pressure as scrutiny of the drug continues to intensify.

Health Risks & Injuries Linked to Tepezza Use

Health risks and injuries linked to Tepezza use mainly involve problems with hearing. Many people who received Tepezza infusions reported new or worsening ear and hearing issues during or after treatment. Some patients developed hearing loss that remained even after the infusions ended. Others experienced tinnitus, which is a constant or recurring ringing or buzzing sound in the ears. There are also reports of a feeling of pressure or fullness in the ears, reduced sound clarity, and sensitivity to noise.

In some cases, the injury appears to be temporary, but in many others, the damage has lasted long after treatment and may be permanent. These problems can interfere with everyday life, including communication, work, sleep, and emotional well-being. Some patients say hearing problems have affected their social life and their ability to function comfortably in public places. Because Tepezza is given to treat a serious eye condition, many users expected to improve their quality of life, but instead, they say they were left with a new medical problem that they were not properly warned about.

Read about the Ozempic Lawsuit Updates

Who Can Join the Tepezza Hearing Loss Lawsuit & How to File?

Many patients who took Tepezza to treat Thyroid Eye Disease are now coming forward because they developed hearing problems that they were not properly warned about. The lawsuit gives affected individuals a way to seek compensation for the harm and long-term impact on their daily lives.

You may qualify to join the Tepezza hearing loss lawsuit if the following apply to you:

• You received one or more Tepezza infusions for Thyroid Eye Disease
• You later developed hearing loss, ringing, buzzing, muffled hearing, ear pressure, or reduced sound clarity
• The hearing problems began during treatment or appeared sometime after treatment ended
• Your hearing issues were not present before Tepezza, or they became much worse after treatment
• You were not clearly informed about the risk of serious or lasting hearing damage when Tepezza was recommended
• You can provide basic proof of treatment and hearing issues, such as medical records, prescription history, or hearing test results

How to File a Tepezza Hearing Loss Claim?

Patients do not file on their own. A lawyer handles the entire legal process, and most firms take the case only if compensation is won.

Steps to move forward:

• Contact a law firm that is currently handling Tepezza hearing loss cases
• Share information about your Tepezza infusions, when symptoms started, and how your hearing problems affect your daily life
• Provide medical records, including any hearing evaluations, so the lawyer can review and confirm your eligibility
• Once you qualify, the lawyer files your claim within the Tepezza litigation and manages all court deadlines and requirements
• Most Tepezza lawyers work on a contingency basis, meaning you do not pay anything upfront, and legal fees come only from a successful settlement or payout

Read about the Transvaginal Mesh Lawsuit

Settlement Status & Compensation Outlook in the Tepezza Lawsuit

The Tepezza hearing loss litigation is ongoing, and many patients are waiting to see how the settlement process develops. A global settlement has not been finalized yet. The cases are currently grouped together in a large multidistrict litigation, and both sides are still exchanging evidence and preparing for the next stages. Early trials that were planned have been delayed, which suggests that settlement talks may be taking place behind the scenes. As of now, most individual cases have not been resolved, and claimants are still in the legal process.

Compensation in this lawsuit will depend on the level of harm that each person experienced. Lawyers expect that payouts will vary based on how serious the hearing injury is, whether the damage is permanent, the age and lifestyle of the patient, and how strongly medical records support the connection to Tepezza. While no confirmed settlement values exist yet, several legal experts and law firms have provided estimates to help injured patients understand what the future may look like.

Current expectations include a wide range. Many standard cases with moderate hearing loss are expected to fall somewhere in the tens of thousands to the low hundreds of thousands. More severe cases with long-lasting or permanent hearing loss are expected to be valued higher, and some legal analysts believe the strongest cases could reach several hundred thousand dollars or more. In any settlement, compensation may cover medical bills, hearing aids or treatment, loss of income, future care, and the effect of the injury on daily life and overall well-being.

It is important to remember that these numbers are estimates and not guarantees. The final amounts will depend on how the litigation progresses, how strong the evidence is, and whether the cases settle or go to trial. If a global settlement is reached, claimants will likely be paid based on a scoring system that weighs the severity of injury and proof of damages. If cases go to live trials, individual results may be higher or lower depending on jury decisions.

As the lawsuit moves forward, the compensation outlook may continue to change. If you want, the next section can cover when a Tepezza settlement might happen, what factors can speed it up, or what evidence increases a person’s payout value.

Read about the OGX Lawsuit updates

Legal Strategies, Court Decisions & What They Mean for the Tepezza Lawsuit

The Tepezza litigation is focused on proving that the drug manufacturer failed to properly warn patients and doctors about the risk of hearing damage. Lawyers representing injured patients are working to show that the company knew or should have known that Tepezza could cause serious hearing problems but did not update the warning label or share the full risk information soon enough. The legal strategy centers on medical studies, internal company records, and the real-life experiences of patients who developed lifelong hearing issues after treatment.

The defense strategy from the company has been aimed at reducing responsibility. It argues that Tepezza is an important treatment for a rare disease and that hearing problems were already listed as a possible side effect in early materials. The company has also questioned whether every claimant can prove that Tepezza directly caused their hearing loss rather than age, existing medical conditions, or unrelated factors. This difference in arguments is shaping how the case is unfolding.

Recent court decisions have allowed many Tepezza cases to move forward together in one coordinated litigation. This approach makes it easier to collect evidence and determine patterns across patients. Judges have also required both sides to exchange large amounts of scientific and medical information so that the court can decide whether the warnings were truly adequate. The removal of early trial deadlines signals that there may be serious settlement discussions in progress because courts often pause trial preparations when both sides show willingness to negotiate.

These legal developments mean that the case is gaining momentum for injured patients. When many plaintiffs are allowed to present similar evidence at once, it increases pressure on the manufacturer to settle rather than risk unpredictable jury verdicts. It also means that the science behind the hearing damage link is being reviewed in a structured and detailed way. As more internal documents and expert testimony come forward, the strength of the claims becomes clearer.

Overall, the legal strategies and court decisions so far suggest that the litigation is moving in a direction that could lead to compensation in the future. The next major milestone will be whether the parties reach a settlement or proceed to test trials. Either outcome will shape how future claims are valued and how quickly claimants may receive financial recovery. If you want, the next section can cover when a settlement might happen or what claimants should do while waiting for updates.

Read about the Batiste Dry Shampoo Cancer Lawsuit

What Comes Next in the Tepezza Hearing Loss Litigation?

The Tepezza lawsuits are moving through important stages, and several key developments are expected in the coming months. Although a final settlement has not yet been reached, the progress of the cases shows that the litigation is entering a phase where major decisions are likely to be made.

The next steps in the litigation include:

• Continued exchange of medical studies, expert reports, and internal company documents to determine what the manufacturer knew about the risk of hearing damage
• Ongoing preparation of a group of strong sample cases that courts will use to measure how juries might react to the evidence
• Additional court hearings will resolve disagreements between both sides about expert testimony, scientific research, and the strength of the warning label
• Pressure on both parties to decide whether a settlement can be reached before trials begin
• A possible claim scoring system, if a settlement is announced, with compensation levels based on the severity of injury and proof of damages

If the parties reach a settlement, claimants will be able to submit documented proof of their Tepezza use and hearing injuries to receive compensation based on the agreed-upon scoring structure. If the case instead goes to trial before a settlement is finalized, early courtroom results will set the tone for how much individual claims may be worth in the future.

For patients who already filed a claim or plan to file one soon, the best course of action is to stay in contact with their lawyer, continue attending medical appointments, and keep copies of hearing tests and treatment records. These steps can improve the strength of the claim once settlement payments begin or trial dates are set.

Read about the Hernia Mesh Lawsuit Update

Frequently Asked Questions (FAQs) About the Tepezza Lawsuit